ROCKVILLE, Md., May 24 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Wednesday, May 30, 2007, at 10:30 a.m. Eastern Time.
The presentation will take place as part of the Friedman Billings Ramsey Growth Conference 2007 at the Grand Hyatt New York, Park Avenue at Grand Central, New York. Dr. Polymeropoulos’ remarks will be available live on the Vanda Web site, where it also will be archived for 30 days.
To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda’s lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda’s second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda’s third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
Vanda Pharmaceuticals Inc.
CONTACT: Steven A. Shallcross, Senior Vice President, Chief FinancialOfficer of Vanda Pharmaceuticals Inc., +1-240-599-4500
Web site: http://www.vandapharma.com//
